Why Faeth Therapeutics Inc (FTH) Stock Is Rising
As of 2026-09-18, Faeth Therapeutics Inc (FTH) has a next-year EPS growth estimate of 78.26%. Featured in 6 EPS revision reports, most recently on 2026-09-07.
Why FTH Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Faeth Therapeutics Inc's next-year EPS growth estimate from 78.49% to 78.56% on 2026-09-14.
- ·Current-Year Growth: Projected at 9.88%, supporting the forward estimate revision.
News Context
FTH’s recent rise is primarily tied to a modest analyst EPS revision, with the next-year growth estimate upgraded to 78.56% from 78.49% on 2026-09-14. The FDA
Generated 2026-09-17 · news as of 2026-09-17
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 78.26%
- EPS growth this year
- 9.88%
- EPS next quarter (est)
- -$0.78
- Last price
- $34.50
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-09-18 | 78.26% | 9.88% | -$0.78 | $34.50 |
| 2026-09-17 | 78.26% | 9.88% | -$0.78 | $35.13 |
| 2026-09-16 | 78.26% | 9.88% | -$0.78 | $34.24 |
| 2026-09-15 | 78.56% | 10.22% | -$0.78 | $35.37 |
| 2026-09-14 | 78.56% | 10.22% | -$0.78 | $39.09 |
| 2026-09-13 | 78.49% | 10.22% | -$0.79 | $37.44 |
| 2026-09-11 | 78.49% | 10.22% | -$0.79 | $37.44 |
| 2026-09-10 | 78.49% | 10.22% | -$0.79 | $39.00 |
| 2026-09-09 | 78.49% | 10.22% | -$0.79 | $36.12 |
| 2026-09-08 | 78.73% | 10.37% | -$0.80 | $39.20 |
| 2026-09-07 | 78.73% | 10.37% | -$0.80 | $40.05 |
| 2026-09-06 | 78.73% | 10.37% | -$0.80 | $40.05 |
| 2026-09-04 | 78.73% | 10.37% | -$0.80 | $40.05 |
| 2026-09-03 | 78.73% | 10.37% | -$0.80 | $39.00 |
| 2026-09-02 | 78.73% | 10.37% | -$0.80 | $39.12 |
| 2026-09-01 | 78.73% | 10.37% | -$0.80 | $34.51 |
| 2026-08-31 | 78.73% | 10.37% | -$0.80 | $32.77 |
| 2026-08-30 | 78.73% | 10.37% | -$0.80 | $33.84 |
| 2026-08-29 | 77.57% | 10.13% | -$0.79 | $33.84 |
| 2026-08-28 | 77.57% | 10.13% | -$0.79 | $33.84 |
| 2026-08-27 | 77.57% | 10.13% | -$0.79 | $33.74 |
| 2026-08-26 | 77.57% | 10.13% | -$0.79 | $32.97 |
| 2026-08-25 | 77.57% | 10.13% | -$0.79 | $34.52 |
| 2026-08-24 | 77.57% | 10.13% | -$0.79 | $34.71 |
| 2026-08-23 | 77.57% | 10.13% | -$0.79 | $32.00 |
| 2026-08-21 | 77.57% | 10.13% | -$0.79 | $32.00 |
| 2026-08-20 | 77.36% | 10.22% | -$0.80 | $32.10 |
| 2026-08-19 | 77.36% | 10.22% | -$0.80 | $33.11 |
| 2026-08-18 | 77.36% | 10.22% | -$0.80 | $33.00 |
| 2026-08-17 | 77.36% | 10.22% | -$0.80 | $32.77 |
Reports Featuring FTH
- 2026-09-07
MNTK Surges 26.7% as EPS Revisions Signal Renewables Strength
- 2026-09-04
RNXT surges 43% as EPS revisions lift penny stocks
- 2026-06-25
FTH Surges 69.8% on EPS Revision; LILA, CRMT Also Jump
- 2026-06-24
FTH Leads EPS Revision Rally with 68.9% Surge; CRMT, LILA Also Gain
- 2026-06-23
FTH +65%, CRMT +65% Lead EPS Revision Surge; RFIL +29%, LILA +24%
- 2026-06-22
Top EPS Revision Winners: OTLK Surges 66%, FTH Gains 60% on Estimate Hikes
Recent News
- Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial CancerBusiness Wire
- Faeth Therapeutics Strengthens Executive Team with Senior Leadership AppointmentsBusiness Wire
- Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific ConferenceBusiness Wire
- Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational UpdatesBusiness Wire
- Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational UpdatesBusiness Wire
- Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst callsThe Fly
- Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in CancerBusiness Wire
- Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateBusiness Wire
Screen Performance
Aggregate stats across all 2047 tickers our top-EPS-revision screen has flagged over the past 170 days.
- Median return since detection
- +0.3%
- % of tickers in the green
- 51%
- Median return on winners
- +22.2%
- Large revisions captured
- 1736
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Faeth Therapeutics Inc (FTH) stock go up recently?▾
Faeth Therapeutics Inc (FTH) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 78.49% to 78.56% on 2026-09-14. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Faeth Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-09-18, Faeth Therapeutics Inc (FTH) has a next-year EPS growth estimate of 78.26%, based on analyst consensus.
When was the latest EPS estimate revision for FTH?▾
The most recent revision occurred on 2026-09-16, when analysts adjusted the next-year EPS growth estimate from 78.56% to 78.26%.
What sector and industry does Faeth Therapeutics Inc belong to?▾
Faeth Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. FTH appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Faeth Therapeutics Inc (FTH) appears here because it was detected by our daily top-EPS-revision-performer screen.